H. Nakanishi et al., Molecular diagnostic detection of free cancer cells in the peritoneal cavity of patients with gastrointestinal and gynecologic malignancies, CANC CHEMOT, 43, 1999, pp. S32-S36
Free cancer cells exfoliated from cancer-invaded serosa contribute to perit
oneal dissemination, the most frequent pattern of recurrence in patients wi
th gastric and ovarian cancers. This study was designed to evaluate the pro
gnostic significance of free cancer cells in peritoneal washes detected usi
ng the reverse transcriptase-polymerase chain reaction (RT-PCR) and cytolog
y. RT-PCR analysis with primers specific for the carcinoembryonic antigen (
CEA) gene was found to be more sensitive than cytology for detection of fre
e tumor cells in the peritoneal washes, collected at laparotomy from 199 ga
stric carcinoma patients, with higher detection rates for each of the T-cat
egories in the TNM classification. Six patients with synchronous and 5 with
recurrent peritoneal dissemination were found among 25 advanced cancer pat
ients with positive PCR and negative cytology results. Positive PCR results
were significantly associated with poor survival of curatively resected ad
vanced gastric carcinoma patients (P < 0.001). A rapid method for detecting
CEA mRNA using the LightCycler and the dsDNA binding dye SYBR green I was
also developed. The results obtained using this technique were essentially
the same as those obtained using the conventional RT-PCR method. Furthermor
e, RT-PCR analysis with primers specific for MUC1 epithelial mucin were per
formed on peritoneal washes from patients with ovarian cancer. Peritoneal w
ashes from 21 of 25 ovarian carcinoma patients, including all 17 with posit
ive cytology results, were positive for MUC1 mRNA, again indicating a highe
r sensitivity using this method than conventional cytology. Highly sensitiv
e and rapid detection of free cancer cells in peritoneal washes, most relia
bly by RT-PCR, is a powerful technique to predict peritoneal dissemination
in patients with gastric and ovarian cancers.